High-content screening with siRNA optimizes a cell biological approach to drug discovery: Defining the role of p53 activation in the cellular response to anticancer drugs

Journal of Biomolecular Screening

Volumn 9, Issue 7, 2004, Pages 557-568

  Giuliano, Kenneth A ^a   Chen, Yih Tai ^a   Taylor, D Lansing ^a   Masucci, Judy P ^a  

^a Department of Marketing Cellomics ^*

Author keywords

Cell based assays; Cluster analysis; High content profiling; High throughput screening; RNA inhibition

Indexed keywords

2 METHOXYESTRADIOL; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; COLCHICINE; CYTOCHALASIN D; DNA; ELLIPTICINE; ETOPOSIDE; FLUOROURACIL; HOMOHARRINGTONINE; LATRUNCULIN B; METHOTREXATE; PACLITAXEL; PROTEIN P53; ROSCOVITINE; SMALL INTERFERING RNA; TUBULIN; VINBLASTINE;

ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CLUSTER ANALYSIS; COMBINATORIAL LIBRARY; CONTROLLED STUDY; CYTOLOGY; CYTOSKELETON; DNA DAMAGE; DNA SYNTHESIS; DRUG MECHANISM; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; KOLMOGOROV SMIRNOV TEST; LUNG CARCINOMA; MICROTUBULE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL CYCLE; CLUSTER ANALYSIS; DNA; DRUG SCREENING ASSAYS, ANTITUMOR; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MODELS, BIOLOGICAL; PACLITAXEL; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 17044431370     PISSN: 10870571     EISSN: None     Source Type: Journal    
DOI: 10.1177/1087057104265387     Document Type: Article

References (30)

1. Collins FS, Morgan M, Patrinos A: The human genome project: lessons from large-scale biology. Science 2003;300:286-290.
2. Collins FS, Green ED, Guttmacher AE, Guyer MS: A vision for the future of genomics research. Nature 2003;422:835-847.
3. Bochner BR: New technologies to assess genotype-phenotype relationships. Nat Rev Genet 2003;4:309-314.
4. Badet GD, Heilbut A, Andrews B, Tyers M, Hughes T, Boone C: Functional genomics and proteomics: charting a multidimensional map of the yeast cell. Trends Cell Biol 2003;13:344-356.
5. Altman RB, Klein TE: Challenges for biomedical informatics and pharmacogenomics. Annu Rev Pharmacol Toxicol 2002;42:113-133.
6. Freimer N, Sabatti C: The human phenome project. Nat Genet 2003;34:15-21.
7. Abraham VC, Taylor DL, Haskins JR: High content screening applied to large-scale cell biology. Trends Biotechnol 2004;22:15-22.
8. Giuliano KA, Haskins JR, Taylor DL: Advances in high content screening for drug discovery. Assay Drug Dev Technol 2003;1:565-577.
9. Giuliano KA, DeBiasio RL, Dunlay RT, Gough A, Volosky JM, Zock J, et al: High-content screening: a new approach to easing key bottlenecks in the drug discovery process. J Biomol Screen 1997;2:249-259.
10. Giuliano KA: High-content profiling of drug-drug interactions: cellular targets involved in the modulation of microtubule drug action by the antifungal ketoconazole. J Biomol Screen 2003;8:125-135.
11. Minguez JM, Giuliano KA, Balachandran R, Madiraju C, Curran DP, Day BW: Synthesis and high content cell-based profiling of simplified analogues of the microtubule stabilizer (+)-discodermolide. Mol Cancer Ther 2002;1: 1305-1313.
12. Wipf P, Reeves JT, Balachandran R, Giuliano KA, Hamel E, Day BW: Synthesis and biological evaluation of a focused mixture library of analogues of the antimitotic marine natural product curacin A. J Am Chem Soc 2000;122:9391-9395.
13. Blagosklonny MV, Pardee AB: Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 2001;61:4301-4305.
14. Borbe R, Rieger J, Weller M: Failure of taxol-based combination chemotherapy for malignant glioma cannot be overcome by G2/M checkpoint abrogators or altering the p53 status. Cancer Chemother Pharmacol 1999;44:217-227.
15. Osaki S, Nakanishi Y, Takayama K, Pei XH, Ueno H, Hara N: Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells. Cancer Gene Ther 2000;7:300-307.
16. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-6311.
17. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990;249:912-915.
18. Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny MV, Fojo T: Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene 2000;19:3078-3085.
19. Daoud SS, Munson PJ, Reinhold W, Young L, Prabhu VV, Yu Q, et al: Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. Cancer Res 2003;63:2782-2793.
20. Ceraline J, Deplanque G, Duclos B, Limacher JM, Hajri A, Noel F, et al: Inactivation of p53 in normal human cells increases G2/M arrest and sensitivity to DNA-damaging agents. Int J Cancer 1998;75:432-438.
21. Arenz C, Schepers U: RNA interference: from an ancient mechanism to a state of the art therapeutic application? Naturwissenschaften 2003;90:345-359.
22. Shuey DJ, McCallus DE, Giordano T: RNAi: gene-silencing in therapeutic intervention. Drug Discov Today 2002;7:1040-1046.
23. Lampariello F: On the use of the Kolmogorov-Smirnov statistical test for immunofluorescence histogram comparison. Cytometry 2000;39:179-188.
24. Watson JV: Proof without prejudice revisited: immunofluorescence histogram analysis using cumulative frequency subtraction plus ratio analysis of means. Cytometry 2001;43:55-68.
25. Young IT: Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. J Histochem Cytochem 1977;25:935-941.
26. Cox C, Reeder JE, Robinson RD, Suppes SB, Wheeless LL: Comparison of frequency distributions in flow cytometry. Cytometry 1988;9:291-298.
27. Peng Y, Li C, Chen L, Sebti S, Chen J: Rescue of mutant p53 transcription function by ellipticine. Oncogene 2003;22:4478-4487.
28. Giannakakou P, Nakano M, Nicolaou KC, O'Brate A, Yu J, Blagosklonny MV, et al: Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci U S A 2002;99:10855-10860.
29. Kwon HJ, Yoshida M, Nagaoka R, Obinata T, Beppu T, Horinouchi S: Suppression of morphological transformation by radicicol is accompanied by enhanced gelsolin expression. Oncogene 1997;15:2625-2631.
30. Zhu H, Bilgin M, Snyder M: Proteomics. Annu Rev Biochem 2003;72:783-812.